Answers are grounded in this paper and cite their sources.
The key neuropathological hallmarks of Alzheimer’s disease (AD) are extracellular deposits of beta-amyloid (Aβ), neurofibrillary tangles composed of hyperphosphorylated tau protein, and progressive neurodegeneration. Approved therapeutic anti-Aβ monoclonal antibodies can reduce amyloid burden and moderately slow clinical decline at early stages of AD. One reason for the limited efficacy of this therapy may be the molecular heterogeneity of Aβ, which comprises a set of proteoforms differing in length, aggregation state, and the presence of molecular modifications. This review discusses structural Aβ proteoforms, alterations in amyloid precursor protein processing, molecular modifications of Aβ, and their contribution to aggregation and toxicity. Particular attention is paid to pathologically relevant proteoforms as promising targets for selective immunotherapy. The therapeutic relevance of such targets is determined not only by the presence of a chemical modification, but also by the aggregation state of Aβ, as well as its availability in brain tissue and the vascular wall. The review discusses approved anti-Aβ antibodies, experimental approaches to optimizing their specificity and delivery across the blood–brain barrier, and strategies for generating and humanizing antibodies against modified forms of Aβ. Neuroinflammation is considered separately as a therapeutic target and a potential component of combination treatment strategies. Current developments in AD therapy are likely to involve a transition from nonspecific removal of amyloid deposits toward more precise targeting of pathogenic Aβ proteoforms in combination with modulation of inflammatory mechanisms.
No takes yet. Share an insight, caveat, or question.
Grigorova et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: